760 related articles for article (PubMed ID: 16163158)
21. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
22. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
23. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC
Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363
[TBL] [Abstract][Full Text] [Related]
24. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
25. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor (VEGF) signaling in tumor progression.
Roskoski R
Crit Rev Oncol Hematol; 2007 Jun; 62(3):179-213. PubMed ID: 17324579
[TBL] [Abstract][Full Text] [Related]
27. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
28. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.
Gaur P; Bielenberg DR; Samuel S; Bose D; Zhou Y; Gray MJ; Dallas NA; Fan F; Xia L; Lu J; Ellis LM
Clin Cancer Res; 2009 Nov; 15(22):6763-70. PubMed ID: 19887479
[TBL] [Abstract][Full Text] [Related]
29. Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Hyder SM
Endocr Relat Cancer; 2006 Sep; 13(3):667-87. PubMed ID: 16954424
[TBL] [Abstract][Full Text] [Related]
30. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.
Sela S; Itin A; Natanson-Yaron S; Greenfield C; Goldman-Wohl D; Yagel S; Keshet E
Circ Res; 2008 Jun; 102(12):1566-74. PubMed ID: 18515749
[TBL] [Abstract][Full Text] [Related]
31. Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis.
Schmidt U; Ahmed J; Michalsky E; Hoepfner M; Preissner R
Genome Inform; 2008; 20():243-51. PubMed ID: 19425138
[TBL] [Abstract][Full Text] [Related]
32. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
33. [Advances of research on vascular endothelial growth factor receptors in epidermal neoplasm].
YANG P; ZHENG M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):422-6. PubMed ID: 19693983
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
36. VEGF function in vascular pathogenesis.
Ng YS; Krilleke D; Shima DT
Exp Cell Res; 2006 Mar; 312(5):527-37. PubMed ID: 16330026
[TBL] [Abstract][Full Text] [Related]
37. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells.
Fons P; Herault JP; Delesque N; Tuyaret J; Bono F; Herbert JM
J Cell Physiol; 2004 Sep; 200(3):351-9. PubMed ID: 15254962
[TBL] [Abstract][Full Text] [Related]
38. Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells.
Yang H; Li M; Chai H; Yan S; Zhang R; Yao Q; Chen C
J Surg Res; 2004 Dec; 122(2):249-55. PubMed ID: 15555625
[TBL] [Abstract][Full Text] [Related]
39. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
40. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
